Audio
Teilen
PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value of $1.65 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers
CLICK HERE TO JOIN
MILWAUKEE, Oct. 8, 2026 /PRNewswire/ -- Ademi LLP is investigating whether the proposed acquisition of Pacira (NASDAQ: PCRX) by Viatris, provides fair value to Pacira's public shareholders and whether Pacira's Board adequately protected shareholder interests in negotiating and approving the transaction.
Are You a PCRX Shareholder?
If you own Pacira shares, Ademi LLP would like to hear from you about the proposed acquisition and your rights as a shareholder.
You may also contact Guri Ademi at gademi@ademilaw.com or toll-free at 866-264-3995. There is no cost or obligation to you.
What Is Ademi LLP Investigating?
The exchange ratio and whether it adequately reflects Pacira's value and future prospects;
Substantial change-of-control benefits available to Pacira insiders in connection with the transaction;
Restrictions on competing transactions, including a significant termination penalty that may discourage another potential buyer from making a superior proposal; and
The conduct of Pacira's Board of Directors in negotiating and approving the transaction and whether the Board fulfilled its duties to public shareholders.
What Should PCRX Shareholders Do?
Contact Ademi LLP to discuss your rights and our investigation. There is no cost or obligation to you.
Guri AdemiAdemi LLP
Toll Free: (866) 264-3995
Email: gademi@ademilaw.com
About Ademi LLP
Ademi LLP represents investors in shareholder litigation involving mergers, acquisitions, buyouts, and individual shareholder rights.
Attorney advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pcrx-shareholder-alert-ademi-llp-investigates-whether-buyout-fairly-values-pacira-biosciences-inc-302902663.html
SOURCE Ademi LLP
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
